Chi, Y. (2018). Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationChi, Y. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationChi, Y. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.